RBDCOV project
"RBD Dimer recombinant protein vaccine against SARSCoV2" (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA. Launched on 1st December, RBDCOV project objective is to test the efficacy, tolerability, and safety of the HIPRA's recombinant COVID-19 vaccine in children, adolescents and immunocompromised people. The trials will last 2.5 years approximately.
About the project
To carry out this project, HIPRA works with an international consortium including companies and institutions from five European countries: Spain (IRSICAIXA, Fundacio Hospital Universitari Vall D’hebron, Fundacion Lucha Contra El Sida (FLS), IDIBAPS, IDIBGI, Asphalion, Vinces Consulting, Zabala Innovation), United Kingdom (Veristat International), Italy (Fondazione Penta), Germany (European Aids Treatment Group), And Turkey (Metpharm Arastirma Gelistirme Saglik Danismanlik). The project will manage a budget of EUR 9.779.211,25 euros.
The RBDCOV project foresees two clinical trials, one in a group of immunocompromised individuals and the second study in one or more groups of children and adolescents. The RBDCOV project will contribute to the development of the HIPRA vaccine which aims to protect against severe COVID-19 infection including in immunocompromised individuals and to ensure a long-term immune response. The Project also envisages that the vaccine will be made accessible for vaccination campaigns worldwide thanks to its 2-8º C storage temperature, which facilitates a longer lasting shelf-life, transport, and distribution.
